Therefore, MS patients can generate function-blocking anti-Gal-8 antibodies with pathogenic potential, as they can neutralize the immunosuppressive role of endogenous Gal-8 that would normally ameliorate CNS inflammation. This evidence concerns the gene LGALS8 and myeloid sarcoma.